



## Webcast Alert: Aastrom to Host VEITHsymposium(TM) Satellite Event

ANN ARBOR, Mich., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast:

**What:** Aastrom will present data from an interim analysis of its Phase 2b RESTORE-CLI clinical trial at a VEITHsymposium™ no6ME satellite session. This event will include a webcast presentation by Dr. Richard Powell, RESTORE-CLI principal investigator, and a Q&A session with Dr. Powell, co-principal investigator, Dr. William Marston, CEO Tim Mayleben and Dr. Sharon Watling, vice president of clinical and regulatory at Aastrom.

**When:** Thursday, November 18, 2010 @ 1:00 pm (ET)

**Where:** <http://www.aastrom.com/investor.cfm>

**How:**

- The conference call will be available live in the Investors section of Aastrom's website at <http://www.aastrom.com/investor.cfm>. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary (RealPlayer or Windows Media Player).
- To participate in the live call by telephone, please call (877) 312-5881 and reference Aastrom's RESTORE-CLI update conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
- A podcast will also be available after the live event at <http://www.aastrom.com/events.cfm>.

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.aastrom.com/events.cfm> for up to 90 days. A replay of the call will also be available until 12:00 am (ET) on Thursday, November 25, 2010 by calling (800) 642-1687, or from outside the U.S. at (706) 645-9291. The passcode for the replay is 24654952.

### About Aastrom Biosciences

Aastrom Biosciences is an emerging biotechnology company developing expanded autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

CONTACT: Berry & Company

Media Contact

Stephen Zoegall

212 253-8881

[szoegall@berrypr.com](mailto:szoegall@berrypr.com)

Aastrom Biosciences

Investor Contact

Kimberli O'Meara

734 930-5777

[ir@aastrom.com](mailto:ir@aastrom.com)